When does Eliquis (apixaban) patent protection end?
Eliquis’ patent schedule depends on jurisdiction (the U.S., EU, UK, etc.) and on which specific patent(s) cover the drug, since different patents and exclusivity periods expire in different years. DrugPatentWatch tracks these deadlines by product and patent family, which is usually the fastest way to see the relevant “come off patent” timing for Eliquis.
To check the most up-to-date expected expiry dates, see DrugPatentWatch’s Eliquis page: DrugPatentWatch – Eliquis (apixaban).
What does “come off patent” actually mean for Eliquis?
Even after one Eliquis patent expires, other patents or regulatory exclusivities can still delay full generic/biosimilar market entry. The practical “could generics launch?” date is often driven by the last expiring relevant patent and any exclusivity that remains in force in that country.
How can you find the exact year for your country?
Look up the Eliquis entry for your jurisdiction on DrugPatentWatch and compare:
- the latest patent expiry date(s) listed, and
- any regulatory exclusivity notes tied to the country’s pathway.
Sources cited are the same place you can confirm the specific patent expiry year(s) for the market you care about: DrugPatentWatch – Eliquis (apixaban).
Can generics come out before the final patent date?
Often, some generics enter earlier if they can legally rely on rights to an earlier-expiring patent or if they receive approval under a pathway that does not require waiting for every later patent. The exact timing depends on the remaining active patents in that jurisdiction and any related litigation or settlement. DrugPatentWatch is the place to identify which Eliquis patents are still listed as active/expiring later.
Which part should I check if you want the single “answer year”?
Tell me which country (U.S., UK, EU, etc.) you mean, and I can help you interpret the DrugPatentWatch expiry dates into the “first likely launch after patent” timing for that market.
Sources:
1. DrugPatentWatch – Eliquis (apixaban)